TG Therapeutics, Inc. (NASDAQ:TGTX) Files An 8-K Other EventsItem 8.01. Other Events.
On February 2, 2018, TG Therapeutics, Inc. (the “Company”) issued a press release announcing results from the Phase 2 multicenter trial of ublituximab (TG-1101), the Company’s novel glycoengineered anti-CD20 monoclonal antibody, in relapsing forms of Multiple Sclerosis (RMS) presented during the 3rd Annual Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2018 in San Diego, CA. A copy of the press release is being filed as Exhibits 99.1and incorporated in this Item by reference.
Item 9.01
Financial Statements And Exhibits.
99.1
Press Release, dated February 2, 2018.
TG THERAPEUTICS, INC. ExhibitEX-99.1 2 v020218_8k.htm V020218_EX991 Untitled Document TG Therapeutics,…To view the full exhibit click here
About TG Therapeutics, Inc. (NASDAQ:TGTX)
TG Therapeutics, Inc. (TG) is a biopharmaceutical company focused on the acquisition, development and commercialization of treatments for b-cell malignancies and autoimmune diseases. The Company is developing over two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a glycoengineered monoclonal antibody that targets a specific epitope on the CD20 antigen found on mature B-lymphocytes. The Company is also developing TGR-1202, an orally available Phosphoinositide 3-kinase (PI3K) delta inhibitor. Both TG-1101 and TGR-1202 are in clinical development for patients with hematologic malignancies. The Company also has pre-clinical programs focusing on developing interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitors and anti-PD-L1 and anti-GITR antibodies. The Company also evaluates complementary products, technologies and companies for in-licensing, partnership, acquisition and investment opportunities.